期刊文献+

Tumstatin活性片段-T7肽抑制血管生成的实验研究

Experimental study on anti-angiogenic activity of T7 peptide derived from active fragment of Tumstatin
下载PDF
导出
摘要 目的:探讨肿瘤抑素(Tumstatin)的活性片段T7肽在体外对血管生成的影响及相关机制。方法:选取人脐静脉内皮细胞(HUVECs)作为研究对象,在模拟肿瘤缺氧微环境的缺氧培养箱内进行相关实验。分为缺氧对照组、缺氧+T7肽(1.0μmol/L)处理组、缺氧+T7肽(2.0μmol/L)处理组。体外小管形成实验观察T7肽在缺氧环境下对血管生成的影响;CCK-8法检测T7肽对HUVECs活力的影响;Annexin V-FITC法检测细胞凋亡情况;Western blot检测Bax、Bcl-2蛋白的表达变化;免疫荧光及Western blot检测HUVECs中VE-钙黏蛋白表达变化。结果 :在缺氧环境下,T7肽可明显抑制体外血管生成(P<0.05),并显著降低HUVECs活力,促进其凋亡(P<0.05);T7肽可诱导促凋亡蛋白BAX表达增加(P<0.05),抗凋亡蛋白Bcl-2表达降低(P<0.01);T7肽可降低HUVECs内VE-钙黏蛋白的表达(P<0.05)。结论:T7肽可通过抑制内皮细胞活力、促进内皮细胞凋亡及降低VE-钙黏蛋白表达发挥其抗血管生成的作用。 Objective: To investigate the influence and related mechanisms of T7 peptide de- rived from tumstatin on angiogenesis in vitro. Methods: HUVECs were incubated in hypoxia chamber(37℃, 1% 02, 5% CO2, 94% N2) to simulate the hypoxic microenvironment in tumors, and grouped into: hypoxia group, hypoxia+T7 peptide (1.0 μmol/L) group, and hypoxia+T7 peptide(2.0μmol/L) group. The tube formation assay was applied to analyze the influence of T7 peptide on an- giogenesis under hypoxia. Cell Counting Kit-8 was applied to observe the cell viability. The apoptosis rate was detected with Annexin V-FITC, and the expression levels of pro-apoptotic protein BAX and anti-apoptotic protein Bcl-2 were observed with western btotl Immunofluorescence and western blot were used to detect the expression of VE-cadherin. Results: Under hypoxic condition, T7 peptide significantly inhibited capillary-like tube formation (P〈0.05), inhibited ECs viability(P〈0.05), and increased the ECs apoptosis rate in vitro; T7 peptide resulted in the downregulation of an- ti-apoptotic protein Bcl-2 (P〈0.01)and upregulation of pro-apoptotic protein BAX(P〈0.05);the ex- pression of VE-cadherin was downregulated by T7 peptide significantly(P〈0.05). Conclusions: T7 peptide could execute its anti-angiogenic activity via inhibition of ECs viability, induction of ECs apoptosis rate, and downregulation of VE-cadherin expression.
出处 《中国现代普通外科进展》 CAS 2017年第8期589-593,共5页 Chinese Journal of Current Advances in General Surgery
基金 国家自然科学基金(81172331) 山东省自然科学基金(ZR2012HL05)
关键词 血管生成 T7肽 细胞活力 细胞凋亡 VE-钙黏蛋白 Angiogenesis.T7 peptide,Cett viability,Cell apoptosis-Ve-cadherin
  • 相关文献

参考文献2

二级参考文献66

  • 1Andreas Pircher,Michael Medinger,Joachim Drevs.Liver cancer:Targeted future options[J].World Journal of Hepatology,2011,3(2):38-44. 被引量:7
  • 2Zhong-Lin Zhang Zhi-Su Liu Quan Sun.Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma[J].World Journal of Gastroenterology,2006,12(26):4241-4245. 被引量:24
  • 3Jemal A,Bray F,Center MM, et al.Global cancer statisticsCA A Cancer Journal for Clinicians,2011.
  • 4Llovet JM,Ricci S,Mazzaferro V,Hilgard P,Gane E,Blanc JF,de Oliveira AC,Santoro A,Raoul JL,Forner A,Schwartz M,Porta C,Zeuzem S,Bolondi L,Greten TF,Galle PR,Seitz JF,Borbath I,Haussinger D,Giannaris T,Shan M,Moscovici M,Voliotis D,Bruix J.Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine . 2008
  • 5Liu L,Cao Y,Chen C,et al.Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research . 2006
  • 6Thomas MB,Morris J S,Chadha R,et al.Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. Journal of Clinical Oncology . 2009
  • 7Abou-Alfa GK,Schwartz L,Ricci S,Amadori D,Santoro A,Figer A,De Greve J,Douillard JY,Lathia C,Schwartz B,Taylor I,Moscovici M,Saltz LB.Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology . 2006
  • 8W rns MA,Schuchmann M,Düber C,Otto G,Galle PR,Weinmann A.Sunitinib in patients with advanced hepato- cellular carcinoma after progression under sorafenib treat- ment. Oncology . 2010
  • 9Finn RS,Kang YK,Mulcahy M,Polite BN,Lim HY,Walters I,Baudelet C,Manekas D,Park JW.Phase II,open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clinical Cancer Research . 2012
  • 10Olivier Mir,Romain Coriat,Pascaline Boudou-Rouquette,Stanislas Ropert,Jean-Philippe Durand,Anatole Cessot,Vincent Mallet,Philippe Sogni,Stanislas Chaussade,Stanislas Pol,Fran?ois Goldwasser.Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib[J]. Medical Oncology . 2012 (4)

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部